AvantGuard
- Company typePrivate
- Founded2018
- HeadquartersIthaca, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
AvantGuard firmographics
Firmographics- Name
- AvantGuard
- Legal name
- AvantGuard, Inc.
- Website
- https://avantguardinc.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
AvantGuard industry classification
Industry- Product category
- Antimicrobial disinfectants and infection control
- NAICS
- Soap and Cleaning Compound Manufacturing (32561), Surface Active Agent Manufacturing (325613)
- SIC
- Miscellaneous Chemical Products (2890), Industrial Organic Chemicals (2860)
- akta.pro primary industry
- Industrial Biocides & Preservatives (IMAEABAH)
- akta.pro secondary industries
- Antibacterial & Medicated Cleansers (e.g., Acne, Antifungal, Antiseptic) (CRABAEAH), Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation) (HLAHALAC), Concentrated Surface Disinfectants (Dilutable Liquids) (CRAJANAB), Hand Sanitizers & Antibacterial Personal Care (CRADANAI)
Keywords
Where AvantGuard is headquartered
LocationHeadquarters
- HQ city
- Ithaca
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AvantGuard business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Antimicrobial Products: Sale of formulated products including AvantSept (antiseptic wash), AvantGel (topical hydrogel), and Avant24 (residual surface disinfectant). Products target healthcare facilities, medical device manufacturers, wound care, and consumer skincare applications.
- Licensing and Technology Partnerships: The company positions its technology as a platform applicable across multiple markets including surface disinfection, dermatology, wound care, and medical devices. Licensing of the Avantamine chemistry to larger healthcare and consumer product companies represents a potential revenue stream.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
AvantGuard product offering
Product offeringCore offering
AvantGuard develops and sells formulated antimicrobial products based on its proprietary Avantamine™ chloramine chemistry. The company offers Polyvantoin Chlorine (residual surface disinfectant), AvantSept (antimicrobial wash), AvantGel (wound care hydrogel), and Avant24 (24-hour surface protection) for healthcare facilities, medical device manufacturers, wound care providers, and dermatology applications.
Product overview
AvantGuard is a biotechnology company developing a platform technology based on its proprietary Avantamine™ molecule - a stabilized chloramine inspired by the human immune system's natural pathogen-fighting chemistry. The core product portfolio includes polyvantoin chlorine (the primary disinfectant formulation combining Avantamine with hydrophilic monomers for stability), available in multiple delivery formats: AvantSept (antimicrobial wash), AvantGel (hydrogel for wound care), and Avant24 (residual surface disinfectant providing 24-hour protection). The platform addresses critical healthcare challenges including Candida auris infections, healthcare-associated infections, dermatophytosis, and diabetic foot ulcer infections, targeting a combined market opportunity exceeding $30 billion across surface disinfection, dermatology, and wound care segments.
Differentiator
Problem solved
Functional benefit
Brands
- Avantamine: Proprietary stabilized chloramine molecule inspired by the body's natural immune defenses, providing broad-spectrum antimicrobial activity without resistance generation or safety issues like skin irritation or surface corrosion.
- AvantSept
- AvantGel
- Avant24
- Polyvantoin chlorine
Products and services
- Polyvantoin Chlorine A polymer-based disinfectant combining Avantamine™ chloramine monomer with hydrophilic monomers to stabilize chlorine in solution. It provides broad-spectrum antimicrobial activity against ESKAPE pathogens, C. auris, and biofilms, with residual surface protection lasting weeks. Targeted at healthcare facilities and infection control applications.
- AvantSept An antimicrobial wash formulation for skin decontamination, wound care, and infection control. Part of AvantGuard's wound care portfolio targeting chronic wounds and diabetic foot ulcers with broad-spectrum efficacy against drug-resistant pathogens and biofilm-forming organisms.
- AvantGel A polyvantoin chlorine hydrogel formulation for wound care and topical antimicrobial treatment of diabetic foot ulcers and skin infections. Provides sustained antifungal and antibacterial activity with demonstrated superiority over standard treatments like silver sulfadiazine and clotrimazole in biofilm eradication models.
- Avant24
Quantifiable outcome
- 100,000x more effective than chlorhexidine against bacterial biofilms
- +5 more outcomes
Companies that use AvantGuard
Customer profileSegments5 records
Ideal customer profiles4 records
AvantGuard technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
AvantGuard partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- DiverseyminorDr. Carine Nkemngong from AvantGuard co-authored a scientific paper with Peter Teska from Diversey on biofilm research and pathogen persistence in healthcare and food processing environments.
- University of MiamicoreResearch collaboration with Dr. Stephen Davis at University of Miami for definitive animal model testing of AvantGel and AvantSept against Pseudomonas aeruginosa and Staphylococcus aureus in an in vivo biofilm eradication porcine model.
- NIAID Pre-Clinical Services / Element Materials TechnologycoreNIH-funded contract testing of polyvantoin chlorine against ESKAPE pathogens at Element Materials Technology under NIAID Pre-Clinical Services program.
- iFybercoreIthaca-based research partner conducting C. auris clade testing (I, II, III, IV) to demonstrate consistent MIC values across different geographic strains.
- Fungus Testing Laboratory at UT Health Science Center San AntoniocoreCLSI-compliant antifungal susceptibility testing (M27 and M38 methodologies) against multiple Candida species and pathogenic fungi.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
AvantGuard competitors and assessment
Company assessmentDirect peers
- Halomine Inc. AvantGuard's parent company; both are founded on the Avantamine chloramine technology platform and target antimicrobial applications in healthcare, food safety, and industrial markets. Most direct technology peer.
- Scynexis: FDA-approved developer of Brexafemme (ibrexafungerp), the first new antifungal class in decades, with active programs targeting Candida auris. Direct peer in antifungal innovation for drug-resistant fungal pathogens.
- Cidara Therapeutics: Developer of Rezzayo (rezafungin), FDA-approved in 2023 for candidemia and invasive candidiasis, with ongoing C. auris development. Direct peer in echinocandin-class antifungals for resistant fungal infections.
Emerging players
- F2G (F2G Biotech): Late-stage clinical biotech developing olorofim, a novel oral antifungal for invasive aspergillosis and rare mold infections including C. auris. Emerging peer in antifungal resistance space with similar unmet-need focus.
- Pulmatrix: Clinical-stage biopharma developing inhaled anti-infectives for respiratory fungal infections. Emerging peer in anti-infective innovation with similar small-cap R&D profile, though different delivery modality.
Broad incumbents
- Ecolab: $70B+ market cap global leader in water, hygiene, and infection prevention with deep hospital and long-term care sales channels. Broad incumbent in surface disinfection where AvantGuard's Avant24 would compete.
- Diversey: Global hygiene and cleaning solutions company (acquired by Solenis); existing AvantGuard research co-author partner (Peter Teska). Broad incumbent in healthcare surface disinfection and a potential licensing partner or competitor.
- Mölnlycke Health Care: Global leader in wound care and surgical solutions, including Mepilex antimicrobial dressings. Broad incumbent in advanced wound care where AvantGuard's AvantGel targets diabetic foot ulcers.
- ConvaTec: Public medical device company with leading wound therapeutics portfolio (Avelle, AQUACEL) including antimicrobial silver dressings. Broad incumbent in advanced wound care segment.
- GOJO Industries (Purell): Inventor of PURELL and dominant player in hand hygiene and skin antiseptic products for healthcare and consumer markets. Broad incumbent in antiseptic wash category where AvantGuard's AvantSept competes.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
AvantGuard social profiles
Digital presenceAvantGuard financial estimates
Financial estimateRevenue estimate
Valuation estimate
AvantGuard leadership team
Management profileNumber of profiles
Profiles4 records
AvantGuard funding detail
Funding detailFunding overview
Funding rounds23 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AvantGuard M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AvantGuard
What does AvantGuard do?
AvantGuard develops and sells formulated antimicrobial products based on its proprietary Avantamine™ chloramine chemistry. The company offers Polyvantoin Chlorine (residual surface disinfectant), AvantSept (antimicrobial wash), AvantGel (wound care hydrogel), and Avant24 (24-hour surface protection) for healthcare facilities, medical device manufacturers, wound care providers, and dermatology applications.
Is AvantGuard a public or private company?
AvantGuard is a private company. It is classified as venture growth investor backed and is currently operating.
When was AvantGuard founded?
AvantGuard was founded in 2018. It employs 1 to 10 people.
Where is AvantGuard based?
AvantGuard is headquartered in Ithaca, United States, in the North America region.
How does AvantGuard make money?
Two revenue lines are on record. Antimicrobial Products are the primary driver. The others are licensing and Technology Partnerships.
Who are AvantGuard's main competitors?
Direct peers on record are Halomine Inc., Scynexis and Cidara Therapeutics. Emerging players are F2G (F2G Biotech) and Pulmatrix. Broad incumbents are Ecolab, Diversey, Mölnlycke Health Care, ConvaTec and GOJO Industries (Purell).
Does AvantGuard have an API?
No public API is recorded for AvantGuard.
What industry is AvantGuard in?
AvantGuard's product category is Antimicrobial disinfectants and infection control. Its primary akta.pro industry code is IMAEABAH, Industrial Biocides & Preservatives, with a secondary code of CRABAEAH, Antibacterial & Medicated Cleansers (e.g., Acne, Antifungal, Antiseptic). Its NAICS code is 32561 and its SIC code is 2890.